Brought to you by 
ContraVir gains rights to Chimerix's Phase I antiviral
02 Feb 2023
Executive Summary
Chimerix Inc. licensed ContraVir Pharmaceuticals Inc. exclusive rights to develop and commercialize CMX157, which is an analog of Gilead’s marketed antiviral Viread (tenofovir).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
ContraVir gains rights to Chimerix's Phase I antiviral
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice